

LETTER to THE EDITOR

Title:

European Academy of Neurology/Movement Disorder Society-European Section's Guidelines on pallidotomy for Parkinson's disease: Let's remain accurate.

Marwan Hariz^{1,2}§, Anthony E. Lang³§, Jeff M. Bronstein⁴, G. Rees Cosgrove⁵, Rob M.A. de Bie⁶, Mahlon R. DeLong⁷, Robert E. Gross⁸, Paul Krack⁹, Joachim K. Krauss, MD¹⁰, Andrew J. Lees², Andres M. Lozano¹¹, José A. Obeso^{12,13,14}, P. Richard Schuurman¹⁵, Jerrold L. Vitek¹⁶

§ These two authors contributed equally.

¹ Department of Clinical Neuroscience, Umeå University, Umeå, Sweden.

² UCL Queen Square Institute of Neurology, London, United Kingdom.

³ The Edmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital & University of Toronto, Toronto, Ontario, Canada.

⁴ Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.

⁵ Neurosurgery Department at The Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

⁶ Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.

⁷ Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.

⁸ Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA.

⁹ Department of Neurology, Inselspital, University Hospital Bern, Bern, Switzerland.

¹⁰ Department of Neurosurgery, Medical School Hannover, Hannover, Germany.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1111/ene.15667](https://doi.org/10.1111/ene.15667)

This article is protected by copyright. All rights reserved.

¹¹ Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

¹² HM CINAC (Centro Integral de Neurociencias Abarca Campal), Fundación Hospitales de Madrid, Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.

¹³ Network Center for Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain.

¹⁴ University CEU-San Pablo, Madrid, Spain.

¹⁵ Department of Neurosurgery, Amsterdam UMC, Amsterdam, The Netherlands.

¹⁶ Department of Neurology, University of Minnesota, Minneapolis, MN, 55455, USA.

Corresponding author:

Marwan Hariz, MD, PhD

Dept. of Clinical Neuroscience, University Hospital, 901 85 Umeå, Sweden

Phone: +46 70 55 11 868. or: +44 7985 642 852

Email: marwan.hariz@umu.se or: m.hariz@ucl.ac.uk

Author Contribution:

Marwan Hariz: Conceptualization, Original draft preparation, Review & editing.

Anthony Lang: Original draft preparation, Review & editing.

Jeff Bronstein: Review & editing.

Rees Cosgrove: Review & editing.

Rob de Bie: Review & editing.

Mahlon DeLong: Review & editing.

Robert Gross: Original draft preparation, Review & editing.

Paul Krack: Review & editing.

Joachim Krauss: Review & editing.

Andrew Lees: Review & editing.

Andres Lozano: Review & editing.

José Obeso: Original draft preparation, Review & editing.

Richard Schuurman: Review & editing.

Jerold Vitek: Original draft preparation, Review & editing.

Total Word Count Counting including everything: 1880

Word Count Text: 728

Running Title: Inaccuracies in European pallidotomy guidelines

Key words: Parkinson's disease; Pallidotomy; Deep brain stimulation; Guidelines; Evidence-based review; GRADE methodology.

Financial Disclosures/Conflict of interest (unrelated to this Letter):

Marwan Hariz: received honoraria from Boston Scientific for lecturing.

Anthony Lang: Funding from AbbVie, Alector, Amylyx, Biogen, BioAdvance, Biohaven, BlueRock, BMS, CoA Therapeutics, Denali, Janssen, Jazz, Lilly, Paladin, Retrophin, Roche, Sun Pharma, and UCB.

Jeff Bronstein: received funding as site investigator from AbbVie Inc., Alexion Pharmaceuticals, Ultragenix Inc., and UC WorldMeds; has also received funding from the National Institute of Environmental Health Sciences (R01 ES031106 01A1)

Rees Cosgrove: received clinical research support from Insightec

Rob de Bie: received research grants from Neuroderm, Medtronic, Parkinson Vereniging.

Mahlon DeLong: no disclosures to report

Robert Gross: consultant for Medtronic, PLC and Abbot Laboratories.

Paul Krack: grants from Swiss National Science Foundation, Roger de Spoelberch Foundation, Bertarelli Foundation, Annemarie Opprecht Foundation, Parkinson Schweiz, Michael J Fox Foundation, Aleva Neurotherapeutics, and Boston Scientific, personal fees (lecturing fees to employing institution/travel expenses to scientific meetings) from Boston Scientific, Bial, and Zambon outside the submitted work.

Joachim Krauss: consultant to Medtronic. He received honoraria for speaking from St. Jude. Grants were obtained from DFG (German Research Foundation).

Andrew Lees: is funded by the Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, and reports consultancies from Britannia Pharmaceuticals and BIAL. He also reports grants and/or research support from the Frances and Renee Hock Fund and honoraria from Britannia Pharmaceuticals, Profile Pharma, UCB, Roche, BIAL, STADA, NordicInfu Care, and NeuroDerm.

Andres Lozano: consultant to Abbott, Boston Scientific, Medtronic, and Functional Neuromodulation.

José Obeso: no disclosures to report

Richard Schuurman: consultant for Medtronic and Boston Scientific on educational matters.

Jerrold Vitek: Serves as a consultant for Cala Health, Medtronic, Boston Scientific and Abbott. He also serves on the Executive Advisory Board for Abbott and is a member of the scientific advisory board for Surgical Information Sciences. He has research support through the National Institutes of Health.

Funding Source: None

To The Editor

The European Academy of Neurology/Movement Disorder Society-European Section (EAN/MDS-ES) recently published guidelines on invasive therapies in the treatment of Parkinson's diseases simultaneously in the *European Journal of Neurology*¹ and in *Movement Disorders*². We are concerned that the Guidelines methods used have resulted in an inadequate documentation and interpretation of the literature on lesion surgery, especially posteroventral pallidotomy. We believe that this has resulted in an erroneous under-appreciation of the utility of this procedure and in Guidelines that conflict with the endorsements of pallidotomy by International Parkinson and Movement Disorders Society (MDS) 2011 and 2018 Evidence Based Medicine reviews^{3,4}, which use different but still widely acceptable methods of assessing the literature and make recommendations on clinical applicability.

The Guidelines conclude by stating that "the evidence for this treatment is weak". Later in the document it is stated: "The Guidelines committee concluded that unilateral pallidotomy can be considered as a treatment option for advanced PD with medically intractable treatment complications in the absence of other more efficacious and better established treatment options for the particular patient, but the recommendation is considered very weak." It is not clear why the initial rating of "weak" was further downgraded to "very weak".

The Guideline recommendations were in part supported by the interpretation that 2 RCTs evaluated (references 77 and 78 in the Guidelines paper) were unblinded. However, both were single-blinded (i.e., evaluator-blinded)^{5,6}, which is the accepted standard for class I evidence. Further, at least five additional randomized studies on pallidotomy⁷⁻¹¹, some with blinded evaluations, were not taken into consideration by the Guidelines.

The Guidelines further state: "Pallidotomy probably reduces complications of therapy (UPDRS-IV)." We would argue that the term "probably" here is very inaccurate. If there is anything regarding pallidotomy that virtually everyone in the movement disorders community with experience in the field of surgical therapies for PD agrees upon, it is the marked and long-lasting beneficial effect of pallidotomy on levodopa-induced dyskinesias. For example, one evaluation

found that “Levodopa Equivalent Daily Doses (LEDD) increased in all patients who were followed for up to 10 years, without recurrence or induction of dyskinesia contralateral to pallidotomy... In conclusion, the long term effect of unilateral pallidotomy on contralateral dyskinesia was highly reproducible and stable over time.”¹² Indeed, it was the solid and robust effect of posteroventral pallidotomy on dopa-induced and dystonia in subjects with advanced PD that paved the way for using this very same brain target in the surgical treatment of non-parkinsonian dystonia, whether by pallidotomy or by pallidal DBS¹³.

We would argue that the weak or very weak recommendation does not concord with the findings of the above-mentioned randomized studies of pallidotomy’s safety and effectiveness. We do understand that the GRADE methodology accounts for important restrictions of literature evaluated in making formal Guideline recommendations. We would argue that certain exclusions in the case of pallidotomy clearly have resulted in unnecessarily and inappropriately strong negative conclusions. Furthermore, the emphasis on studies that randomize patients between an invasive surgical therapy and medical therapy may be no better or in fact may be worse than the study methods excluded given the strong potential for a lessebo-like effect that diminishes the potential for clinical benefit in patients who have consented to possible surgery (likely wishing to receive this) who find themselves randomised to the open-label medical arm¹⁴.

In conclusion, as the EAN/MDS-ES’s Guidelines confirm, it is evident that DBS in either STN or GPi is a highly evidence-based, established and recommended procedure, its main advantage being to allow a safe simultaneously performed bilateral surgery compared to pallidotomy that should not be performed simultaneously bilaterally. However, if DBS is not available or affordable, or if the patient is not a good candidate for DBS or prefers not to have implanted hardware, the recommendation of posteroventral pallidotomy “as a treatment option for advanced PD with medically intractable treatment complications...for the particular patient” should not be considered “weak” nor “very weak” if it is based on a proper review and evaluation of the published literature on unilateral pallidotomy for advanced PD. In fact, there are no new data that would justify the degradation of the previous strong endorsement of pallidotomy by the MDS as “efficacious”^{3,4}. Furthermore, the recent approval by the Food and

Drug Administration of pallidotomy by Magnetic Resonance-guided Focused Ultrasound provides additional support for the efficacy of pallidotomy¹⁵.

References

1. Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology/Movement Disorder Society—European section guideline on the treatment of Parkinson’s disease: I. invasive therapies. *Eur J Neurol*. 2022;29(9):2580–2595. <https://doi.org/10.1111/ene.15386>
2. Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology/Movement Disorder Society-European section guideline on the treatment of Parkinson’s disease: I. invasive therapies. *Mov Disord*. 2022;37(7):1360–1374. <https://doi.org/10.1002/mds.29066>
3. Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. *Mov Disord*. 2011;26(Suppl 3):S2–S41.
4. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Movement disorder society evidence-based medicine committee. *Mov Disord*. 2018;33(8):1248–1266.
5. Vitek JL, Bakay RA, Freeman A, et al. Randomized trial of pallidotomy versus medical therapy for Parkinson’s disease. *Ann Neurol*. 2003;53(5):558–569.
6. de Bie RM, de Haan RJ, Nijssen PC, et al. Unilateral pallidotomy in Parkinson’s disease: a randomised, single-blind, multicentre trial. *Lancet*. 1999;354(9191):1665–1669.
7. Lozano AM, Lang AE, Galvez-Jimenez N, et al. Effect of GPi pallidotomy on motor function in Parkinson’s disease. *Lancet*. 1995;346:1383–1387.
8. Ondo WG, Jankovic J, Lai EC, et al. Assessment of motor function after stereotactic pallidotomy. *Neurology*. 1998;50:266–270.

9. Merello M, Nouzeilles MI, Cammarota A, Betti O, Leiguarda R. Comparison of 1-year follow-up evaluations of patients with indication for pallidotomy who did not undergo surgery versus patients with Parkinson's disease who did undergo pallidotomy: a case control study. *Neurosurgery*. 1999;44:461–467.
10. Merello M, Nouzeilles MI, Kuzis G, et al. Unilateral radiofrequency lesion versus electrostimulation of posteroventral pallidum: a prospective randomized comparison. *Mov Disord*. 1999;14:50–56.
11. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. *Neurology*. 2004;62:201–207.
12. Rodriguez-Oroz MC, Moro E, Krack P. Long-term outcomes of surgical therapies for Parkinson's disease. *Mov Disord*. 2012;27(14):1718–1728.
13. Hariz M, Blomstedt P. Leksell's Posteroventral Pallidotomy 1992-2022: quo Vadis? *Stereotact Funct Neurosurg*. 2022;100(4):259–263. <https://doi.org/10.1159/000524248>
14. Mestre TA, Espay AJ, Marras C, Eckman MH, Pollak P, Lang AE. Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. *Mov Disord*. 2014 Dec;29(14):1751–1756.
15. Eisenberg HM, Krishna V, Elias WJ, et al. MR-guided focused ultrasound pallidotomy for Parkinson's disease: safety and feasibility. *J Neurosurg*. 2020;27:1–7. <https://doi.org/10.3171/2020.6>.